

Basingstoke, Southampton and Winchester

District Prescribing Committee (DPC)

Recommendations of the meeting of 13th June 2017

Supported or limited support e.g. Specialist recommendation

- **Levosimendan in cardiac surgery**- Following consideration of the evidence, including recent study data, Levosimendan was supported for restricted use only in life threatening post-operative low cardiac output syndrome where the patient is on maximum therapy (catecholamines) and phosphodiesterase inhibitors are contra-indicated/not tolerated and, rarely, preoperatively for patients with very low cardiac output/ejection fraction (e.g. LVEF <25%). It should be classed as a RED drug (specialist only).
- **Aviptadil / Phentolamine (Invicorp) intracavernosal injection for erectile dysfunction** - licensed for the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic or mixed aetiology. It is supported as a third line option in patients who have failed oral treatment and either fail treatment with, or experience unacceptable pain with intracavernosal alprostadil. It should be classed as an Amber drug with initiation in secondary care (Urology clinic).
- **Rheumatology shared care guidelines** - These were approved for use and will be available on the shared care guidelines section of the West Hampshire CCG website shortly (see links below).
- **Melatonin for sleep disorders in children shared care guidelines** - These were approved for use and will be available on the shared care guidelines section of the West Hampshire CCG website shortly (see links below).

Not supported

- **Desmopressin (Noqdirna)** orodispersible tablets are the first desmopressin preparation licensed for symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults, including those over 65 years of age. They are not licensed for use in children. Based on the evidence for efficacy, safety and cost effectiveness, the DPC does not support the use of Noqdirna at this time. GPs should not initiate desmopressin for this indication. Adults with unexplained nocturia should be referred for specialist diagnosis and management.

Other Information

- **Nystatin oral suspension** – the dose for oral candidiasis in BNF has historically reflected posology recommendations (PRs) in the Nystan® SPC. Following discussions with MHRA, the recommended dose has been updated (live in digital versions of BNF from March 2017) and now reflects current PRs for generic nystatin products. The doses are as follows:-

Oral candidiasis in infants (1 month to 2 years) - **1ml should be dropped into the mouth four times a day**

Denture sores, and oral infections in children (≥ 2 years) and adults caused by *Candida albicans* - **1ml of the suspension should be dropped into the mouth four times daily; it should be kept in contact with the affected areas as long as possible.**

- **Antibacterial prophylaxis (AP) prior to dental treatment** –
The Wessex Cardiac Forum and Southampton Cardiac Surgeons' have decided to adopt the European Society of Cardiology (ESC) guidance 2015 in favour of NICE guidance. This recommends AP in high risk groups (past history of IE, prosthetic heart valves, any heart valve repaired with prosthetic material, unrepaired cyanotic heart disease and other certain repairs of congenital heart defects) and prior to the following dental procedures; extractions, descaling, root canal manipulation or any perforation of the oral mucosa or manipulation of gingival or peri-apical region of the teeth.
The ESC guidance currently recommends 2 g orally of Amoxicillin or 600 mg of Clindamycin (for penicillin allergic individuals) orally 30 to 60 minutes pre-procedure. This may differ slightly from current UK recommended doses. The DPC supports this decision.

- DPC summaries are available at: <http://www.westhampshireccg.nhs.uk/downloads/categories/medicines/district-prescribing-committee>
- Guidance documents are available at: <http://www.westhampshireccg.nhs.uk/downloads/categories/medicines/guidance>

Summarised on behalf of the District Prescribing Committee by Andrea White (Southampton City CCG) 28/06/17